keyword
MENU ▼
Read by QxMD icon Read
search

CKD and vitamin D

keyword
https://www.readbyqxmd.com/read/29782253/-mineral-and-bone-disorders-in-chronic-heart-failure
#1
E V Reznik, I G Nikitin
In many patients, chronic heart failure (CHF) is associated with chronic kidney disease (CKD). Virtually all patients with terminal CKD and many patients with early CKD display various disorders of mineral and bone metabolism (MBM) related with all-cause mortality and high risk of cardiovascular complications. This review addressed disorders of mineral and bone metabolism in patients with CHF, including hypocalcemia, hyperphosphatemia, vitamin D insufficiency/deficiency, secondary hyperparathyroidism, changed levels of FGF23 and Klotho, osteoporosis, osteopenia, their clinical and prognostic significance, and possibilities of their correction...
2018: Kardiologiia
https://www.readbyqxmd.com/read/29767854/emerging-association-between-parathyroid-hormone-and-anemia-in-hemodialysis-patients
#2
REVIEW
Motoko Tanaka, Hirotaka Komaba, Masafumi Fukagawa
Anemia is a common complication of chronic kidney disease (CKD). There are various causes of renal anemia such as decreased production of erythropoietin, resistance to erythropoietin, shortened survival of red blood cells, and bone marrow fibrosis. Secondary hyperparathyroidism (SHPT) is a less recognized, but potentially significant cause of renal anemia in CKD patients. Parathyroid hormone (PTH) has been regarded as a uremic toxin that has multiple adverse effects, and its elevated levels have been associated with renal anemia in hemodialysis patients...
May 16, 2018: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/29766695/analysis-of-nutrition-and-nutritional-status-of-haemodialysis-patients
#3
Anna Bogacka, Anna Sobczak-Czynsz, Elżbieta Kucharska, Małgorzata Madaj, Katarzyna Stucka
Background: Chronic kidney disease (CKD) is a common disease of civilization where nutrition is part of the treatment. Diet therapy is difficult as it is necessary to control the intake of: energy, protein and minerals – Na, K, Ca and P in the daily food rations (DFR). Objective: The aim of the study was to assess the nutritional status and diets of haemodialysis (HD) patients. Material and method: The study involved 141 haemodialysis patients, at the average age of 65...
2018: Roczniki Państwowego Zakładu Higieny
https://www.readbyqxmd.com/read/29753401/vitamin-d-and-calcimimetics-in-cardiovascular-disease
#4
REVIEW
Kenneth Lim, Takayuki Hamano, Ravi Thadhani
Cardiovascular disease has earned its place as one of the leading noncommunicable diseases that has become a modern-day global epidemic. The increasing incidence and prevalence of chronic kidney disease (CKD) has added to this enormous burden, given that CKD is now recognized as an established risk factor for accelerated cardiovascular disease. In fact, cardiovascular disease remains the leading cause of death in the CKD population, with significant prognostic implications. Alterations in vitamin D levels as renal function declines has been linked invariably to the development of cardiovascular disease beyond a mere epiphenomenon, and has become an important focus in recent years in our search for new therapies...
May 2018: Seminars in Nephrology
https://www.readbyqxmd.com/read/29748907/effect-of-combined-vitamin-d-receptor-activator-and-lanthanum-carbonate-on-serum-fibroblast-growth-factor-23-level-in-predialysis-patients-cvd-laf-study-design-and-method
#5
Eri Ito, Daijo Inaguma, Shigehisa Koide, Kazuo Takahashi, Hiroki Hayashi, Midori Hasegawa, Yukio Yuzawa
BACKGROUND: Whether vitamin D receptor activator (VDRA) use is beneficial in chronic kidney disease (CKD) is unclear, because it is possible that VDRA increases serum fibroblast growth factor 23 (FGF23) levels. We will conduct a randomized controlled trial in predialysis patients to determine the effect of VDRA alone or in combination with lanthanum carbonate (LC) on serum FGF23 levels. METHODS: This is a single-center, open-label, randomized controlled trial. Enrollment will commence February 1, 2018, using the following inclusion criteria: (1) age ≥ 20 years, (2) CKD with an estimated glomerular filtration rate of 10-45 mL/min/1...
May 10, 2018: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29738034/evaluation-of-prevalence-biochemical-profile-and-drugs-associated-with-chronic-kidney-disease-mineral-and-bone-disorder-in-11-dialysis-centers
#6
Rodrigo Reis Abrita, Beatriz Dos Santos Pereira, Neimar da Silva Fernandes, Renata Abrita, Rosalia Maria Nunes Henriques Huaira, Marcus Gomes Bastos, Natália Maria da Silva Fernandes
INTRODUCTION: The diagnosis and treatment of mineral and bone disorder of chronic kidney disease (CKD-MBD) is a challenge for nephrologists and health managers. The aim of this study was to evaluate the prevalence, biochemical profile, and drugs associated with CKD-MBD. METHODS: Cross-sectional study between July and November 2013, with 1134 patients on dialysis. Sociodemographic, clinical, and laboratory data were compared between groups based on levels of intact parathyroid hormone (iPTH) (< 150, 150-300, 301-600, 601-1000, and > 1001 pg/mL)...
May 7, 2018: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/29733462/current-and-potential-therapeutic-strategies-for-the-management-of-vascular-calcification-in-patients-with-chronic-kidney-disease-including-those-on-dialysis
#7
REVIEW
Irene Ruderman, Stephen G Holt, Tim D Hewitson, Edward R Smith, Nigel D Toussaint
Patients with CKD have accelerated vascular stiffening contributing significantly to excess cardiovascular morbidity and mortality. Much of the arterial stiffening is thought to involve vascular calcification (VC), but the pathogenesis of this phenomenon is complex, resulting from a disruption of the balance between promoters and inhibitors of calcification in a uremic milieu, along with derangements in calcium and phosphate metabolic pathways. Management of traditional cardiovascular risk factors to reduce VC may be influential but has not been shown to significantly improve mortality...
May 7, 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29691773/etelcalcetide-for-treating-secondary-hyperparathyroidism-an-evidence-review-group-evaluation-of-a-nice-single-technology-appraisal
#8
Micah Rose, Jonathan Shepherd, Petra Harris, Karen Pickett, Joanne Lord
The manufacturer of the calcimimetic drug etelcalcetide was invited to make an evidence submission as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) programme. Within this submission, they reported evidence on the clinical and cost effectiveness of etelcalcetide for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on haemodialysis. The Southampton Health Technology Assessments Centre (SHTAC), part of the Wessex Institute at the University of Southampton, was the independent Evidence Review Group (ERG) commissioned to appraise the company's submission...
April 25, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29668990/vitamin-d-receptor-activation-raises-soluble-thrombomodulin-levels-in-chronic-kidney-disease-patients-a-double-blind-randomized-trial
#9
Graziella D'arrigo, Patrizia Pizzini, Sebastiano Cutrupi, Rocco Tripepi, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali
Background: Thrombomodulin (TM) is a proteoglycan highly represented in the endothelial glycocalix that regulates the haemostasis and the endothelial response to inflammation. High soluble TM levels underlie a lower risk for coronary heart disease in population studies. Activation of vitamin D receptor (VDR) upregulates TM, but the effect of this intervention on soluble TM has never been tested in chronic kidney disease (CKD) patients. Methods: We performed a post hoc analysis of a 12 weeks double blind, randomized, placebo-controlled trial testing the effect of VDR activation by paricalcitol (PCT) on endothelium-dependent flow-mediated vasodilatation (FMD) in the forearm (ClinicalTrials...
April 13, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29665793/assessing-known-chronic-kidney-disease-associated-genetic-variants-in-saudi-arabian-populations
#10
Cyril Cyrus, Samir Al-Mueilo, Chittibabu Vatte, Shahanas Chathoth, Yun R Li, Hatem Qutub, Rudaynah Al Ali, Fahad Al-Muhanna, Matthew B Lanktree, Khaled Riyad Alkharsah, Abdullah Al-Rubaish, Brian Kim-Mozeleski, Brendan Keating, Amein Al Ali
BACKGROUND: Genome wide association studies of patients with European descent have identified common variants associated with risk of reduced estimated glomerular filtration rate (eGFR). A panel of eight variants were selected to evaluate their association and prevalence in a Saudi Arabian patient cohort with chronic kidney disease (CKD). METHODS: Eight genetic variants in four genes (SHROOM3, MYH9, SLC7A9, and CST3) were genotyped in 160 CKD patients and 189 ethnicity-matched healthy controls...
April 17, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/29661746/effects-of-oral-vitamin-d-3-supplementation-in-stage-3-chronic-kidney-disease-subjects-insulin-resistance-syndrome-and-hormonal-disturb-interactions
#11
Amina Tahar, Faiza Zerdoumi, Messaoud Saidani, Lakhdar Griene, Elhadj-Ahmed Koceir
The 1-25-hydroxyvitamine D (1-25OHD) or calcitriol deficiency in chronic kidney disease (CKD) patients was associated with increases vascular calcification risk, nephrons reduction, bone deficit and cardiovascular mortality by atherosclerosis. The objective of this study was to investigate the pleiotropic effects of 200.000 IU (D200 group) every 3 months versus 30.000 IU (D30 group) every month dose vitamin D supplementation in stage 3 CKD patients. A cohort of 132 adult subjects was randomized into 2 groups according to dose vitamin D supplementation in deficient subjects (25OHD <50 nmol/L or <20 ng/mL)...
April 16, 2018: Annales de Biologie Clinique
https://www.readbyqxmd.com/read/29658832/the-associations-between-hypovitaminosis-d-higher-pth-levels-with-bone-mineral-densities-and-risk-of-the-10-year-probability-of-major-osteoporotic-fractures-in-chinese-patients-with-t2dm
#12
Xiao-Feng Wang, Jing-Jia Yu, Xiao-Jing Wang, Yi-Xuan Jing, Li-Hao Sun, Bei Tao, Wei-Qing Wang, Guang Ning, Jian-Min Liu, Hong-Yan Zhao
OBJECTIVE: In the current study, we investigated the vitamin D status, and its relationships with parathyroid hormone (PTH) levels, bone mineral density (BMD), and the 10-year probability of fractures in Chinese patients with type 2 diabetes mellitus (T2DM). METHODS: This was a cross-sectional study of 785 patients. BMDs at the lumbar spine (L2-4), femoral neck (FN), and total hip (TH) were measured by dual-energy X-ray absorptiometry (DXA). Serum levels of 25-hydroxyvitamin D (25(OH)D) and intact PTH were also quantified...
April 2018: Endocrine Practice
https://www.readbyqxmd.com/read/29628139/drug-repurposing-in-kidney-disease
#13
REVIEW
Usha Panchapakesan, Carol Pollock
Drug repurposing, is the re-tasking of known medications for new clinical indications. Advantages, compared to de novo drug development, include reduced cost and time to market plus the added benefit of a known pharmacokinetic and safety profiles. Suitable drug candidates are identified through serendipitous observations, data mining, or increased understanding of disease mechanisms. This review highlights drugs suited for repurposing in kidney disease. The main cause of mortality in patients with chronic kidney disease is cardiovascular disease...
April 6, 2018: Kidney International
https://www.readbyqxmd.com/read/29621752/fibroblast-growth-factor-23-a-biomarker-of-kidney-function-decline
#14
David A Drew, Ronit Katz, Stephen Kritchevsky, Joachim H Ix, Michael G Shlipak, Anne B Newman, Andy Hoofnagle, Linda Fried, Mark J Sarnak, Orlando M Gutierrez
BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a hormone that regulates phosphorus levels and vitamin D metabolism. Previous studies have shown FGF-23 to be a risk factor for incident end-stage renal disease; however, there are less data on the association of FGF-23 with earlier kidney-related outcomes. METHODS: Serum FGF-23 was assayed using an intact ELISA assay in 2,496 participants of the Healthy Aging and Body Composition Study, a cohort of well-functioning older adults...
April 5, 2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29619868/fibroblast-growth-factor-23-is-a-strong-predictor-of-insulin-resistance-among-chronic-kidney-disease-patients
#15
Ahmed Fayed, Mahmoud M El Nokeety, Ahmed A Heikal, Dina O Abdulazim, Mervat M Naguib, Usama A A Sharaf El Din
Insulin resistance (IR) is very common among chronic kidney disease (CKD) patients. Disturbance in mineral and bone metabolism (MBD) seems to play a role in the pathogenesis of insulin resistance. Fibroblast growth factor-23 (FGF23) is evolving as the most important link between MBD and many pathologic sequences of CKD. The aim was to evaluate IR in pre-dialysis CKD patients looking for a possible association to mineral metabolism among CKD patients. A total of 100 stage 3-5 CKD patients were selected beside 20 normal control subjects...
November 2018: Renal Failure
https://www.readbyqxmd.com/read/29614098/a-novel-calcimimetic-agent-evocalcet-mt-4580-khk7580-suppresses-the-parathyroid-cell-function-with-little-effect-on-the-gastrointestinal-tract-or-cyp-isozymes-in-vivo-and-in-vitro
#16
Takehisa Kawata, Shin Tokunaga, Miki Murai, Nami Masuda, Waka Haruyama, Youji Shoukei, Yutaka Hisada, Tetsuya Yanagida, Hiroshi Miyazaki, Michihito Wada, Tadao Akizawa, Masafumi Fukagawa
Cinacalcet hydrochloride (cinacalcet), an oral calcimimetic agent has been widely used for the management of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD). In sharp contrast to vitamin D receptor activators, cinacalcet suppresses SHPT without inducing hypercalcemia or hyperphosphatemia. Nevertheless, some patients remain refractory to SHPT with this agent, as the dose cannot be sufficiently increased due to gastrointestinal symptoms. In order to resolve this issue, we have developed a newly synthesized calcimimetic agent, evocalcet (MT-4580/KHK7580)...
2018: PloS One
https://www.readbyqxmd.com/read/29608804/relationship-between-vitamin-d-receptor-gene-polymorphism-and-susceptibility-to-chronic-kidney-disease-and-periodontal-disease-in-community-dwelling-elderly
#17
A Yoshihara, N Kaneko, M Iwasaki, K Nohno, H Miyazaki
OBJECTIVES: The aim of this study was to investigate the possible correlation between vitamin D receptor (VDR) gene polymorphism and susceptibility to chronic kidney disease (CKD) and periodontal disease. MATERIAL AND METHODS: This study analyzed 345 participants, who were all 79 years of age. Kidney function levels were determined based on the estimated glomerular filtration rate (eGFR) (non-reduced function: ≥60, and reduced function: <60 mL/min/1.73 m2 )...
April 2, 2018: Journal of Clinical Periodontology
https://www.readbyqxmd.com/read/29603070/high-calcium-phosphate-and-calcitriol-supplementation-leads-to-an-osteocyte-like-phenotype-in-calcified-vessels-and-bone-mineralisation-defect-in-uremic-rats
#18
Sarah-Kim Bisson, Roth-Visal Ung, Sylvain Picard, Danika Valade, Mohsen Agharazii, Richard Larivière, Fabrice Mac-Way
A link between vascular calcification and bone anomalies has been suggested in chronic kidney disease (CKD) patients with low bone turnover disease. We investigated the vascular expression of osteocyte markers in relation to bone microarchitecture and mineralization defects in a model of low bone turnover CKD rats with vascular calcification. CKD with vascular calcification was induced by 5/6 nephrectomy followed by high calcium and phosphate diet, and vitamin D supplementation (Ca/P/VitD). CKD + Ca/P/VitD group (n = 12) was compared to CKD + normal diet (n = 12), control + normal diet (n = 8) and control + Ca/P/VitD supplementation (n = 8)...
March 30, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29597237/vitamin-d-and-secondary-hyperparathyroid-states
#19
Cristiana Cipriani, Jessica Pepe, Luciano Colangelo, Salvatore Minisola
The interplay between vitamin D and parathyroid hormone (PTH) represents one of the most important metabolic mechanisms of regulation of the calcium/phosphorus homeostasis. Secondary hyperparathyroidism is therefore a major complication that arises as a result of reduced vitamin D levels, both as primary 25-hydroxy-vitamin D (25[OH]D) and/or 1,25-dihydroxyvitamin D (1,25[OH]2D) reduction. Different metabolic pathways are involved, as well as target organs and tissues, with several clinical complications. The skeleton is primarily involved, but many other extra-skeletal organs expressing the vitamin D and/or PTH receptors may theoretically be affected by vitamin D inadequacy and secondary hyperparathyroidism...
2018: Frontiers of Hormone Research
https://www.readbyqxmd.com/read/29581540/lower-serum-calcium-is-independently-associated-with-ckd-progression
#20
Cynthia J Janmaat, Merel van Diepen, Alessandro Gasparini, Marie Evans, Abdul Rashid Qureshi, Johan Ärnlöv, Peter Barany, Carl-Gustaf Elinder, Joris I Rotmans, Marc Vervloet, Friedo W Dekker, Juan Jesus Carrero
Disturbances in calcium metabolism are common in individuals with chronic kidney disease (CKD), but whether they are associated with subsequent kidney function decline is less clear. In a CKD 3-5 cohort of 15,755 adult citizens of Stockholm with creatinine tests taken during 2006-2011 and concurrent calcium testing at cohort entry, we investigated the association between baseline serum calcium and the subsequent change in estimated glomerular filtration rate (eGFR, by CKD-EPI) decline using linear mixed models...
March 26, 2018: Scientific Reports
keyword
keyword
44112
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"